Encodia, a San Diego protein‑sequencing company that developed a DNA‑tagging approach called ProteoCode, ceased operations late last year and is liquidating lab assets, GenomeWeb reported. The startup, founded by veterans of next‑generation sequencing, filed an assignment for the benefit of creditors on Nov. 7, 2025. Encodia had raised prior venture capital and a $75 million Series C in 2021. The shutdown underscores commercialization and capital challenges for novel proteomics platforms that require heavy instrumentation and long sales cycles to reach clinical and research adoption.